Haoyan Zhou

Company: Eli Lilly & Co.

Job title: Director

Bio:

Dr. Haoyan (Michael) Zhou is Director of Non-Viral Delivery at Eli Lilly, where he leads efforts to advance next-generation nucleic acid and oligonucleotide therapies. With over a decade of experience spanning Lilly, Spark Therapeutics, GSK, and Frontage Laboratories, he has built deep expertise in formulation development, biocatalysis, and late-stage gene therapy drug product design. Dr. Zhou earned his PhD in Biomedical Engineering from Case Western Reserve University and brings a strong track record of scientific leadership and innovation to accelerating the development of transformative medicines.

Seminars:

Fireside Discussion: Overcoming Barriers in Repeat Dosing & Dose Escalation of LNP Therapeutics 4:00 pm

Exploring how PEGylation impacts repeat dosing, including the development of anti-PEG antibodies, their effect on clearance and efficacy, and strategies to optimize PEG amount, chain length, and alternatives to minimize immune responses Discussing non-clinical and clinical biomarkers that inform on cumulative toxicity, highlighting translational markers that correlate with human outcomes and guide safety margins, dose…Read more

day: Conference Agenda